Ocular Therapeutix posted a Q2 net loss of $78.76 million, or $0.35 per share, widening from a $67.81 million loss a year earlier.
Revenue was $13.48 million, essentially flat versus the prior-year quarter, while R&D spending rose to $54.14 million.
Selling and marketing expense climbed to $17.28 million, while general and administrative costs increased to $22.16 million.
Cash position and outlook
Cash and cash equivalents totaled $598.64 million at June 30, with runway expected into 2028.
AXPAXLI wet AMD NDA submission remains on track for Q4 2026 following FDA Type C meeting alignment; Ocular plans a 505(b)(2) filing that could shorten review by up to 60 days.
OCUL•
